# Professor Ian Chi Kei Wong

## **Academic qualifications**

- University of Manchester, PhD in Clinical Pharmacology, 1995-1997;
- MSc in Clinical Pharmacology, 1993-1995;
- University of Sunderland, BSc Hons in Pharmacy, 1988-1991

# Previous academic positions

- Head of Department of Pharmacology and Pharmacy, HKU (2018-2023)
- Chair Professor of Pharmacy Practice and Medicine Evaluation Research, Department of Practice and Policy, University College London (UCL) School of Pharmacy (2015-2018)
- Head and Professor of Department of Pharmacology and Pharmacy, HKU, (2011-2015).
- Reader then Professor, The School of Pharmacy, University of London (2002-2011)

#### Present academic position

Regius Professor of Pharmacy, School of Pharmacy, Aston University (2024 – Present)

Lo Shiu Kwan Kan Po Ling Endowed Professor in Pharmacy, Department of Pharmacology and Pharmacy, HKU (2018 – Present)

# Previous relevant research grant in mental health disorders

HONG KONG RESEARCH GRANTS COUNCIL. GENERAL RESEARCH FUND (17126722). Antidepressant Discontinuation and the association of Suicide (ADS). HK\$961,091, (2022/2023)

HONG KONG RESEARCH GRANTS COUNCIL. GENERAL RESEARCH FUND (17114921). RIsk factors in Mother and Autism spectrum disorder in offspring (RIMA). HK\$1,056,156 (2021/2022)

HONG KONG RESEARCH GRANTS COUNCIL. GENERAL RESEARCH FUND (17112020). DIAbetes in Mother and Off-spring with Neurodevelopmental Disorder – ADHD (DIAMOND-A). HK\$ 837,006 (2020/2021)

HONG KONG RESEARCH GRANTS COUNCIL. COLLABORATIVE RESEARCH FUND (C7009-19G) International Big Data Network for Attention Deficit and / Hyperactivity Disorder: Development and Application of Data Platform. HK\$2,203,537 (2019/2020)

HONG KONG RESEARCH GRANTS COUNCIL. GENERAL RESEARCH FUND (17125419) Treatment for Attention Deficit Hyperactivity Disorder and Poisoning: Pharmacoepidemiological Research (TAPPER) HK\$ 339,770 (2019/2020)

# Selected Publications in mental health (\*senior author or corresponding author)

Man KKC, Häge A, Banaschewski T, Inglis SK, Buitelaar J, Carucci S, Danckaerts M, Dittmann RW, Falissard B, Garas P, Hollis C, Konrad K, Kovshoff H, Liddle E, McCarthy S, Neubert A, Nagy P, Rosenthal E, Sonuga-Barke EJS, Zuddas A, Wong ICK\*, Coghill D; ADDUCE Consortium. Long-term safety of methylphenidate in children and adolescents with ADHD: 2-year outcomes of the Attention Deficit Hyperactivity Disorder Drugs Use Chronic Effects (ADDUCE) study. *Lancet Psychiatry*. 2023 May;10(5):323-333.

Luo H, Lau WCY, Chai Y, Torre CO, Howard R, Liu KY, Lin X, Yin C, Fortin S, Kern DM, Lee DY, Park RW, Jang JW, Chui CSL, Li J, Reich C, Man KKC, <u>Wong ICK</u>\*. *JAMA Psychiatry*. Rates of Antipsychotic Drug Prescribing Among People Living With Dementia

During the COVID-19 Pandemic. 2023 Mar 1;80(3):211-219. doi: 10.1001/jamapsychiatry.2022.4448.

Brauer R, Alfageh B, Blais JE, Chan EW, Chui CSL, Hayes JF, Man KKC, Lau WCY, Yan VKC, Beykloo MY, Wang Z, Wei L, <u>Wong ICK</u>\*. Psychotropic medicine consumption in 65 countries and regions, 2008-19: a longitudinal study. *Lancet Psychiatry*. 2021 Dec;8(12):1071-1082. doi: 10.1016/S2215-0366(21)00292-3.

Wang Z, Chan AYL, Coghill D, Ip P, Lau WCY, Simonoff E, Brauer R, Wei L, <u>Wong ICK</u>\*, Man KKC. Association Between Prenatal Exposure to Antipsychotics and Attention-Deficit/Hyperactivity Disorder, Autism Spectrum Disorder, Preterm Birth, and Small for Gestational Age. *JAMA Intern Med.* 2021 Oct 1;181(10):1332-1340. doi: 10.1001/jamainternmed.2021.4571. PMID: 34398171

Man KKC, Lau WCY, Coghill D, Besag FMC, Cross JH, Ip P, Wong ICK. *Lancet Child Adolesc Health*. Association between methylphenidate treatment and risk of seizure: a population-based, self-controlled case-series study. 2020 Jun;4(6):435-443. doi: 10.1016/S2352-4642(20)30100-0. PMID: 32450123

<u>Wong ICK</u>, Banaschewski T, Buitelaar J, Cortese S, Döpfner M, Simonoff E, Coghill D; European ADHD Guidelines Group. Emerging challenges in pharmacotherapy research on attention-deficit hyperactivity disorder-outcome measures beyond symptom control and clinical trials. *Lancet Psychiatry*. 2019 Jun;6(6):528-537.

Hayes JF, Lundin A, Wicks S, Lewis G, Wong ICK, Osborn DPJ, Dalman C. Association of Hydroxylmethyl Glutaryl Coenzyme A Reductase Inhibitors, L-Type Calcium Channel Antagonists, and Biguanides With Rates of Psychiatric Hospitalization and Self-Harm in Individuals With Serious Mental Illness. *JAMA Psychiatry*. 2019 Apr 1;76(4):382-390. doi: 10.1001/jamapsychiatry.2018.3907.

Raman SR, Man KKC, Bahmanyar S, Berard A, Bilder S, Boukhris T, Bushnell G, Crystal S, Furu K, KaoYang YH, Karlstad Ø, Kieler H, Kubota K, Lai EC, Martikainen JE, Maura G, Moore N, Montero D, Nakamura H, Neumann A, Pate V, Pottegård A, Pratt NL, Roughead EE, Macias Saint-Gerons D, Stürmer T, Su CC, Zoega H, Sturkenbroom MCJM, Chan EW, Coghill D, Ip P, Wong ICK\*. Trends in attention-deficit hyperactivity disorder medication use: a retrospective observational study using population-based databases. *Lancet Psychiatry*. 2018 Oct;5(10):824-835. doi: 10.1016/S2215-0366(18)30293-1. Epub 2018 Sep 13.

Man KKC, Coghill D, Chan EW, Lau WCY, Hollis C, Liddle E, Banaschewski T, McCarthy S, Neubert A, Sayal K, Ip P, Schuemie MJ, Sturkenboom MCJM, Sonuga-Barke E, Buitelaar J, Carucci S, Zuddas A, Kovshoff H, Garas P, Nagy P, Inglis SK, Konrad K, Häge A, Rosenthal E, Wong ICK\*icide Attempts With Methylphenidate Treatment. *JAMA Psychiatry*. 2017 Oct 1;74(10):1048-1055. doi: 10.1001/jamapsychiatry.2017.2183.

Man KKC, Chan EW, Ip P, Coghill D, Simonoff E, Chan PKL, Lau WCY, Schuemie MJ, Sturkenboom MCJM, Wong ICK\*. Prenatal antidepressant use and risk of attention-deficit/hyperactivity disorder in offspring: population based cohort study. *BMJ*. 2017 May 31;357:j2350. doi: 10.1136/bmj.j2350.

#### Other relevant experience:

Member of European ADHD Guidelines Group. Since 2013

Member of Attention Deficit Hyperactivity Disorder (ADHD) Guideline Group. National Institute for Health and Clinical Excellence (NICE). 2016-2018.

Member of Attention Deficit Hyperactivity Disorder (ADHD) Guideline Group. National Institute for Health and Clinical Excellence (NICE) (2007-2009)